Keith Wilson

VP CMC & Manufacturing at Amal Therapeutics

Keith has a PhD in Biochemical Immunology with more than 20 years of experience in Biopharmaceutical R&D. After 2 years post-doctoral studies, Keith’s initial experience was in Analytical Sciences at GSK Biopharmaceutical Development in the UK. Subsequently, he moved to Lonza Biologics to head up the Analytical Method Development team and then as Technical Director. Keith moved to Geneva in 2014 to join Novimmune as Head of Bioprocess R&D and led the CMC development and initial commercial manufacturing of emapalumab as well as the development of a number of other monoclonal and bi-specific antibodies. Keith joined AMAL Therapeutics in October 2021 from Swedish Orphan Biovitrum, who acquired emapalumab and related assets from Novimmune in July 2019.